Litigation Facts


Here are the details in some of the Risperdal cases:

  • In 2008, six teenage boys sued J&J after they developed breasts while taking Risperdal. Two of the boys in the lawsuit required mastectomies.

  • In January 2010, state attorneys general, the Department of Justice and others challenged J&J's false claims in a Risperdal lawsuit. The government alleges that between 1999 and 2004, J&J paid $50 million to the pharmaceutical supply company Omnicare to increase Risperdal sales at nursing homes. Omnicare settled its own lawsuit against the government for $112 million.

  • In August 2011, Massachusetts filed a Risperdal lawsuit against J&J for advertising secondary uses of the medication, which were not on the label. The complaint also cited failure to disclose serious Risperdal side effects including the increased risk of diabetes and death in elderly patients. Several other states have filed suits with the same allegations against J&J.

  • In May 2012, the Kentucky attorney general filed a lawsuit claiming that J&J hid the serious side effects of Risperdal and Invega.

  • By September 2012, more than 130 Risperdal and/or Invega (another atypical antipsychotic medication from Janssen) lawsuits involving gynecomastia in boys and young men had been filed against J&J and Janssen Pharmaceuticals.

  • In October 2012, J&J agreed to settle five Risperdal gynecomastia lawsuits filed in Pennsylvania state court.

  • In November 2013, J&J reached the third largest drug company settlement in U.S. history with the Justice Department for $2.2 billion in civil and criminal fines. The case flagged the company's misleading Risperdal advertisements for the treatment of children, seniors and others with disabilities between 1999 and 2005.

  • In January 2014, the Louisiana Supreme Court reversed a $257.7 million jury verdict in favor of the state.


    1 (855) 631-1491